cyclo(alanylalanyl) has been researched along with 3-aminobenzamide in 1 studies
| Studies (cyclo(alanylalanyl)) | Trials (cyclo(alanylalanyl)) | Recent Studies (post-2010) (cyclo(alanylalanyl)) | Studies (3-aminobenzamide) | Trials (3-aminobenzamide) | Recent Studies (post-2010) (3-aminobenzamide) |
|---|---|---|---|---|---|
| 5 | 0 | 3 | 908 | 2 | 111 |
| Protein | Taxonomy | cyclo(alanylalanyl) (IC50) | 3-aminobenzamide (IC50) |
|---|---|---|---|
| Poly [ADP-ribose] polymerase 2 | Mus musculus (house mouse) | 9.81 | |
| Poly [ADP-ribose] polymerase 1 | Homo sapiens (human) | 6.7238 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, PG; Patel, BD | 1 |
1 review(s) available for cyclo(alanylalanyl) and 3-aminobenzamide
| Article | Year |
|---|---|
Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
Topics: Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Humans; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Structure-Activity Relationship | 2019 |